Today: 9 June 2026
PSLV stock pops as silver rebounds from record-high whipsaw; Fed minutes in focus

PSLV stock pops as silver rebounds from record-high whipsaw; Fed minutes in focus

NEW YORK, December 30, 2025, 11:51 ET — Regular session.

  • Sprott Physical Silver Trust (PSLV) rose about 4% in Tuesday trading, tracking a rebound in silver.
  • Silver recovered after Monday’s sharp drop tied in part to higher futures margin requirements.
  • Investors are watching Federal Reserve minutes due later Tuesday for clues on the 2026 rate path.

Sprott Physical Silver Trust rose 4.4% to $25.33 in late-morning trade on Tuesday, after swinging between $24.58 and $25.45. The trust’s U.S.-listed units were up $1.06 from Monday’s close, with volume around 9.8 million shares.

The move put PSLV back in step with the metal it holds after a sudden bout of volatility jolted the silver market into year-end. For investors who use exchange-traded products as a liquid proxy for bullion, the last two sessions have been a reminder that leverage and liquidity can matter as much as the macro story.

The next catalyst lands later Tuesday, when minutes from the U.S. Federal Reserve’s December meeting are released. Any shift in how traders handicap rate cuts can quickly move the dollar and Treasury yields — two key inputs for precious metals pricing.

Spot silver rose 4.6% to $75.523 an ounce after touching an all-time high of $83.62 on Monday before posting its biggest daily drop since August 2020. Analysts at Societe Generale pointed to the CME Group’s decision to raise initial margin requirements — the collateral required to hold futures positions — as a trigger for the selloff. “Things have stabilised somewhat today,” said Peter Grant, vice president and senior metals strategist at Zaner Metals. Reuters

The iShares Silver Trust, a larger U.S. silver ETF, gained 4.7% to $69.11 on Tuesday, underscoring how closely silver-linked funds have tracked the metal’s rebound.

PSLV is a closed-end trust that holds physical silver bars rather than futures contracts. Its net asset value, or NAV — the per-unit value of the underlying silver after expenses — was $24.76 at Monday’s close, while the market price finished at $24.27, a 1.97% discount, Sprott data showed. The trust held about 209.4 million ounces of silver, with total net assets of roughly $15.1 billion.

The dollar’s direction remains an added variable for metals traders, especially in thin holiday markets. The dollar index rose 0.13% to 98.13 ahead of the Fed minutes, and analysts cautioned against over-reading late-December price action given light volumes.

For investors in PSLV, the main question is whether Tuesday’s rebound turns into a steadier uptrend or another leg of whipsaw trading. The last two sessions have shown how quickly forced selling in futures can spill into ETFs and trusts tied to the spot price.

Traders will also watch whether tighter futures margins keep volatility elevated into the new year. Higher margin requirements can cool speculative positioning by making it more expensive to carry large, leveraged bets.

Because PSLV is a closed-end vehicle, it can trade above or below NAV depending on demand for its units. A widening discount can leave holders lagging the spot silver move, while a narrowing discount can amplify gains when sentiment turns.

Stock Market Today

  • Pfizer Shares Drop Premarket Despite New FDA Approval for Hemophilia Drug
    June 9, 2026, 9:26 AM EDT. Pfizer shares declined 1.7% premarket to $25.62 following FDA approval of an expanded label for its hemophilia treatment Hympavzi, now authorized for patients aged 6 and older, including those with inhibitors-antibodies reducing clotting-factor therapy effectiveness. The drug offers a weekly subcutaneous injection alternative to frequent intravenous infusions. Despite the regulatory win, investor focus remains on Pfizer's obesity drug berobenatide, a monthly GLP-1 receptor agonist, competing with Novo Nordisk and Eli Lilly in weight loss treatments. Pfizer reported Q1 revenue of $14.5 billion, up 2% operationally, maintaining 2026 guidance of $59.5-$62.5 billion revenue and $2.80-$3.00 adjusted earnings per share, though earnings fell to 75 cents. Market reaction reflects caution over the company's longer path to profit growth amid patent expirations and competition.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next
Previous Story

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target
Next Story

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target

Go toTop